Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
about
Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cellsNEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV targetTargeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.Systematic analysis of a xenograft mice model for KSHV+ primary effusion lymphoma (PEL)Kaposi's Sarcoma-Associated Herpesvirus Hijacks RNA Polymerase II To Create a Viral Transcriptional Factory.Newly emerging therapies targeting viral-related lymphomas.Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategiesCD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomasMolecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesisAnti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitorsCD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosisA role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma.Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.Large B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challenge.Prognosis in primary effusion lymphoma is associated with the number of body cavities involved.Molecular studies and therapeutic targeting of Kaposi's sarcoma herpesvirus (KSHV/HHV-8) oncogenesis.Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Current status of treatment for primary effusion lymphoma.Primary effusion lymphoma in the absence of HIV infection--clinical presentation and management.Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.Virus reactivation: a panoramic view in human infectionsTherapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.
P2860
Q28481321-4A2538FC-8377-47FC-B183-EAE3153CEB50Q28544735-7D540923-289C-493D-923B-61C2987CDCACQ30408885-C3F9BB29-010C-404C-9A0B-32DBFF1E85FAQ30414412-246A3F1C-855B-4A3B-A6B6-EE895A4C3821Q33690895-AFF286EA-392D-463B-81D9-199F3FF60558Q33699201-161E0F7F-C21D-437C-920C-CCE1DBEBBA95Q34245230-FE8CC20D-C0EE-437E-9081-151411DBC619Q34460823-9B1063F6-D724-4909-82FF-DF8D82F7BC8DQ35046691-D31FE781-4904-47E6-862D-58E91F28109FQ35124404-A674B905-D8F0-45B8-9BE6-64C3D30657F7Q35832168-7F01D78E-D121-4F50-AAB8-0833179E8239Q36890993-E32158A6-5518-4F84-915C-00556824C77AQ36968066-697E21A0-917F-465C-A649-3D1A19151B1DQ37098844-00D330A3-7A8E-407A-A764-A53911221604Q37417526-E17256E3-0F79-4BE5-BB27-CDB8F50D4FC2Q37683385-4951FC15-84DC-4D8D-BE15-75570B1D52FFQ37810431-FEFE151A-C6E6-4021-B285-181D2DE349EFQ37910910-45158DD1-EB75-43B5-BAE1-B821DDA8DE7FQ38010467-B96BDEDF-549C-4117-8C0D-0CF9A9622590Q38160783-0C181E91-F4E9-4DD6-8662-D9D036EAF513Q38194434-654C1C0F-8880-42C1-A3B8-9CF1C1D382FBQ38227506-38FDFB56-2791-47C2-B4F2-5BFDF4100F5BQ38264454-F8D0121D-0799-4269-8409-C831A7B2F96EQ38270091-5EBE1460-8955-4F20-9AB8-2E16E6796A78Q38449592-DA9E1288-1773-413C-B760-8CF0094ACB50Q38605346-A56245FD-9712-406B-AB54-570DD7DF487EQ38943741-61EE3712-EF8A-4C30-9493-5B98AAEE5420Q39103566-D589D8B6-2B16-4F56-8AF0-232DC6B14DC6Q39723484-E750F8A0-8DA8-49ED-8CA3-D3D297F8FD48Q45324502-BAC6E3FE-FAFA-426A-9E41-35C337DE1C5FQ48330061-D8C65014-BF70-496E-9C0A-B2BC41375C63
P2860
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@ast
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@en
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@nl
type
label
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@ast
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@en
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@nl
prefLabel
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@ast
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@en
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@nl
P2093
P2860
P356
P1476
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
@en
P2093
Andrew J Gentles
Enrique A Mesri
Izidore S Lossos
Juan Carlos Ramos
Lucas E Cavallin
Ngoc L Toomey
Shruti Bhatt
Wilfredo Blasini
Yasodha Natkunam
P2860
P304
13069-13074
P356
10.1073/PNAS.1002985107
P407
P577
2010-07-06T00:00:00Z